Blood test to predict complications in AML treatment
Part of Blood & lymphatic, Cancer clinical trials.
This study checks a simple blood test called the D-index to see how well it predicts infections or other complications during standard chemotherapy for newly diagnosed acute myeloid leukemia (AML). It may help doctors better manage your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been newly diagnosed with acute myeloid leukemia (AML) for the first time (not a relapse or on top of another blood disorder).
- You are feeling well enough to do most daily activities on your own (ECOG score 0-2).
- Your doctor plans to give you standard strong chemotherapy (like 7+3 or HiDAC).
- You do not have a rare subtype called acute promyelocytic leukemia (APL).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether a protein called IL-6 can help predict how well chemotherapy will work in people with acute myeloid leukemia (AML) who haven't been treated before. It aims to find better ways to personalize treatment.
This study looks at whether geriatric (age-related health) evaluations help doctors choose better treatment for newly diagnosed AML (a type of leukemia). It may help translate older adults’ needs into a clearer, safer treatment plan.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
This study tests a new blood test to help predict whether acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will come back after a stem cell transplant. Early detection could help doctors treat relapse sooner.
This study looks at how blood counts and clotting change in adults newly diagnosed with acute myeloid leukemia (AML) who receive a strong type of chemotherapy. It aims to better understand how to manage these patients during treatment.
This study uses a special blood test to see if it can predict which patients with a specific type of acute myeloid leukemia (AML with MLL changes) are more likely to relapse or have better survival. The test may help doctors plan better treatment.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.